Literature DB >> 18523820

High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis.

J F Carvalho1, V S T Viana, E F Borba, A P do Nascimento, E P Leon, L A Testagrossa, R T Barros, E Bonfá.   

Abstract

The antichromatin antibody (aCT) has been described as a useful marker for lupus nephropathy. The relevance of its nephritogenic potential may be appropriately evaluated in the context of renal histopathology. Therefore, the present study investigated the relationship of aCT with a particular histopathologic class of lupus nephritis (LN). Seventy-eight consecutive patients with systemic lupus erythematosus (ACR criteria) and active nephritis who underwent renal biopsy from 1999 to 2004 and with available frozen serum sample obtained at the time of biopsy were selected. aCT was measured by ELISA, and anti-dsDNA was measured by indirect immunofluorescence (IIF) and by ELISA. All renal biopsies were revised in a blinded manner by the same expert renal pathologist. Charts were extensively reviewed for demographic and renal features obtained at the time of biopsy. The prevalence of aCT (>or=20 U) was 59% with a mean titer of 74.3 +/- 38.7 U. Both aCT-positive and aCT-negative groups of patients had similar age, gender distribution, duration of lupus, and duration of renal disease. Anti-dsDNA was detected by IIF in 29.5% and by ELISA in 42.3% of the patients. Concomitant presence of both antibodies was observed in 63% (29/46) [anti-dsDNA by ELISA] and 45.6% (21/46) [anti-dsDNA by IIF] of the patients. Lower serum levels of C3 (73% vs. 40%, P = 0.0058) and C4 (82% vs. 46.7%, P = 0.0021) were more commonly observed in aCT >or= 20 U patients compared to the aCT-negative group. It is important to note that the use of a higher cut-off value (>or=40 U) for aCT test revealed a predominance of class IV LN (58% vs. 33%, P = 0.039) in aCT >or= 40 U compared to aCT < 40 U group. The mean levels of proteinuria, serum albumin, and creatinine were markedly altered but were comparable in both groups (P >or= 0.05). One fourth (26.3%) of the 19 patients with class IV LN and aCT >or= 40 U had no detectable anti-dsDNA (ELISA). These data suggest that high-titer aCT seems to be a valuable biomarker for proliferative class IV of LN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523820     DOI: 10.1007/s10067-008-0939-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 2.  Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins.

Authors:  M H Foster; B Cizman; M P Madaio
Journal:  Lab Invest       Date:  1993-11       Impact factor: 5.662

Review 3.  Systemic lupus erythematosus.

Authors:  B L Kotzin
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

4.  Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis.

Authors:  Yves Renaudineau; Sabine Croquefer; Sandrine Jousse; Eric Renaudineau; Valérie Devauchelle; Paul Guéguen; Catherine Hanrotel; Boris Gilburd; Alain Saraux; Yehuda Shoenfeld; Chaim Putterman; Pierre Youinou
Journal:  Arthritis Rheum       Date:  2006-08

5.  Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody.

Authors:  D J Min; S J Kim; S H Park; Y I Seo; H J Kang; W U Kim; C S Cho; H Y Kim
Journal:  Clin Exp Rheumatol       Date:  2002 Jan-Feb       Impact factor: 4.473

6.  Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis.

Authors:  Morris Reichlin; Marianne Wolfson-Reichlin
Journal:  Clin Immunol       Date:  2003-07       Impact factor: 3.969

7.  Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients.

Authors:  S Saisoong; S Eiam-Ong; O Hanvivatvong
Journal:  Clin Exp Rheumatol       Date:  2006 Jan-Feb       Impact factor: 4.473

8.  Autoantibodies in lupus nephritis patients requiring renal transplantation.

Authors:  L M Stinton; S G Barr; L A Tibbles; S Yilmaz; A Sar; H Benedikttson; M J Fritzler
Journal:  Lupus       Date:  2007       Impact factor: 2.911

9.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

10.  Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease.

Authors:  D Koffler; R Carr; V Agnello; R Thoburn; H G Kunkel
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

View more
  2 in total

1.  Male gender results in more severe lupus nephritis.

Authors:  Jozélio Freire de Carvalho; Ana Patrícia do Nascimento; Leonardo A Testagrossa; Rui Toledo Barros; Eloísa Bonfá
Journal:  Rheumatol Int       Date:  2009-09-27       Impact factor: 2.631

2.  SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus.

Authors:  Michael A Smith; Jill Henault; Jodi L Karnell; Melissa L Parker; Jeffrey M Riggs; Dominic Sinibaldi; Devon K Taylor; Rachel Ettinger; Ethan P Grant; Miguel A Sanjuan; Roland Kolbeck; Michelle A Petri; Kerry A Casey
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.